[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-exocrine-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-exocrine-insufficiency":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100626914","phase-3-pancreatic-enzyme-replacement-in-acute-necrotizing-pancreatitis-100626914",false,"NCT07441824","Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis","Effect of Pancreatic Enzyme Replacement Therapy in Patients With Acute Necrotizing Pancreatitis: A Multicenter Double Blinded Randomised Placebo Controlled Trial","PERiANP","Inclusion Criteria:\n\n* Patients diagnosed with AP according to the Revised Atlanta Classification diagnostic criteria\n* Index episode of acute pancreatitis with more than 50% pancreatic parenchymal necrosis and at least 5% loss of pre pancreatitis body weight at the time of screening\n* Within 6 weeks of onset of disease\n* Able to take food orally\n* Age 18-60 years\n* Both genders\n\nExclusion Criteria:\n\n* Underlying chronic pancreatitis\n* Recurrent acute pancreatitis\n* Pancreatic cancer\n* Patients being discharged with NJ tubes\n* Pregnancy and lactation\n* Inability to give informed consent.","ALL","18 Years","60 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with \\>50% pancreatic parenchymal necrosis and at least 5% loss of body weight.\n\nThe primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.",[28,29],"Acute Necrotizing Pancreatitis","Pancreatic Exocrine Insufficiency",[31,32,33],"acute pancreatitis","pancrearic exocrine insufficiency","pancreatic enzyme replacement therapy","RECRUITING","2026-04-29",{"date":37,"type":38},"2026-05-05","ACTUAL",{"date":40,"type":38},"2026-04-10",{"date":42,"type":22},"2027-06",{"name":44,"class":45},"Asian Institute of Gastroenterology, India","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100634087","ipex-study-pancreatic-exocrine-insufficiency-as-a-functional-marker-of-disease-progression-in-patients-with-ipmn-100634087","NCT07535125","IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN","IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN Under Surveillance","IPEX","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of BD-IPMN, MD-IPMN, or mixed IPMN\n* Under active imaging surveillance\n* Signed informed consent\n\nExclusion Criteria:\n\n* Prior pancreatic surgery\n* Chronic pancreatitis\n* Known pancreatic ductal adenocarcinoma at baseline\n* Other established causes of PEI unrelated to IPMN",{"count":56,"type":22},600,"OBSERVATIONAL","Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk. However, IPMN pathophysiology includes ductal obstruction by mucin, chronic ductal hypertension, and progressive parenchymal atrophy, mechanisms that may lead to pancreatic exocrine insufficiency (PEI).\n\nPEI is a maldigestion syndrome typically associated with chronic pancreatitis, pancreatic cancer, and pancreatic surgery, but it has never been systematically investigated in patients with IPMN under surveillance.\n\nThe IPEX study is a multicenter prospective observational cohort study designed to evaluate whether PEI is prevalent in IPMN patients and whether it correlates with morphologic disease progression. The study also evaluates the potential role of PEI as a functional marker complementary to imaging criteria in IPMN surveillance.",[60,29],"Intraductal Papillary Mucinous Neoplasms",[62,63,60],"Functional Marker","pancreatic exocrine insufficiency","NOT_YET_RECRUITING","2026-04-09",{"date":67,"type":38},"2026-04-16",{"date":69,"type":22},"2026-07-01",{"date":71,"type":22},"2027-12-31",{"name":73,"class":45},"A.O.U. Città della Salute e della Scienza"]